FibroBiologics is pursuing a development program for CYPS317 with the goal of advancing first-in-human clinical trials following FDA review of the IND filing. The IND submission includes comprehensive ...

On May 16, 2025, FibroBiologics, Inc. (NASDAQ:FBLG) announced a poster presentation at the Society for Investigative Dermatology (SID) Annual Meeting. The poster entitled “Immunomodulatory Potential ...

HOUSTON, March 19, 2024 /PRNewswire/ -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the ...

In a new finding, researchers from Barts Cancer Institute at Queen Mary University, London, have discovered more about how fibroblasts actually help pancreatic cancer develop, raising the possibility ...

On February 12, 2025, Fibrobiologics, Inc. (NASDAQ:FBLG) held an Analyst Day and provided a comprehensive update on the ...

FibroBiologics (NASDAQ:FBLG) is continuing preparations for a Phase 1/2 trial of CYWC628, a fibroblast-based spheroid product candidate, in patients suffering from diabetic foot ulcers (DFUs), which ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre® (pemigatinib), a selective fibroblast ...

Age-related changes in the fibroblasts, cells that create the skin's structure, contribute to the development of aggressive, treatment-resistant melanoma in males, according to new research.

EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (OTC: FCSC) today announced that its Phase 2 study to evaluate the safety and efficacy of azficel-T (LAVIV®) for the treatment of patients with ...

A recent study published in the Nutrients Journal evaluated the effects of phenolic compounds in extra virgin olive oil (EVOO) on the proliferation, cell cycle, migration, and antigenic profile of ...